Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Eggink D, Bontjer I, Langedijk JP, Berkhout B, Sanders RW.

J Virol. 2011 Oct;85(20):10785-97. doi: 10.1128/JVI.05331-11. Epub 2011 Aug 10.

2.

Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.

He Y.

Curr Pharm Des. 2013;19(10):1800-9. Review.

PMID:
23092277
3.

Inhibition of HIV-1 by fusion inhibitors.

Eggink D, Berkhout B, Sanders RW.

Curr Pharm Des. 2010;16(33):3716-28. Review.

PMID:
21128887
4.

Molecular strategies to design an escape-proof antiviral therapy.

Berkhout B, Sanders RW.

Antiviral Res. 2011 Oct;92(1):7-14. doi: 10.1016/j.antiviral.2011.04.002. Epub 2011 Apr 12. Review.

PMID:
21513746
5.

The current status and challenges in the development of fusion inhibitors as therapeutics for HIV-1 infection.

Tan JJ, Ma XT, Liu C, Zhang XY, Wang CX.

Curr Pharm Des. 2013;19(10):1810-7. Review.

PMID:
23092283
6.

Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.

Yu F, Lu L, Du L, Zhu X, Debnath AK, Jiang S.

Viruses. 2013 Jan 11;5(1):127-49. doi: 10.3390/v5010127. Review.

7.

Peptide and non-peptide HIV fusion inhibitors.

Jiang S, Zhao Q, Debnath AK.

Curr Pharm Des. 2002;8(8):563-80. Review.

PMID:
11945159
8.

Development of small molecule HIV-1 fusion inhibitors: linking biology to chemistry.

Miyamoto F, Kodama EN.

Curr Pharm Des. 2013;19(10):1827-34. Review.

PMID:
23092276
9.

HIV-1 gp41: mediator of fusion and target for inhibition.

Weiss CD.

AIDS Rev. 2003 Oct-Dec;5(4):214-21. Review.

PMID:
15012000
10.

Is there a future for antiviral fusion inhibitors?

Berkhout B, Eggink D, Sanders RW.

Curr Opin Virol. 2012 Feb;2(1):50-9. doi: 10.1016/j.coviro.2012.01.002. Epub 2012 Jan 28. Review.

PMID:
22440966
11.

Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).

Zhang D, Li W, Jiang S.

Expert Opin Ther Pat. 2015 Feb;25(2):159-73. doi: 10.1517/13543776.2014.987752. Epub 2014 Nov 27. Review.

PMID:
25428639
12.

Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.

Garg H, Viard M, Jacobs A, Blumenthal R.

Curr Top Med Chem. 2011 Dec;11(24):2947-58. Review.

13.

Inhibiting HIV-1 entry with fusion inhibitors.

Baldwin CE, Sanders RW, Berkhout B.

Curr Med Chem. 2003 Sep;10(17):1633-42. Review.

PMID:
12871113
14.

Discovery of small molecule fusion inhibitors targeting HIV-1 gp41.

Zhou G, Chu S.

Curr Pharm Des. 2013;19(10):1818-26. Review.

PMID:
23092284
15.

Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

De Feo CJ, Weiss CD.

Viruses. 2012 Dec;4(12):3859-911. Review.

16.

Peptides in the treatment of AIDS.

Naider F, Anglister J.

Curr Opin Struct Biol. 2009 Aug;19(4):473-82. doi: 10.1016/j.sbi.2009.07.003. Epub 2009 Jul 23. Review.

Items per page

Supplemental Content

Write to the Help Desk